ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2196 • ACR Convergence 2022

    Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System

    Philip J Mease1, Qi Wei2, Michael Chiorean1, Lulu Iles-Shih1, Wanessa Matos2, Andrew Baumgartner2, Sevda Molani2, Yeon Mi Hwang2, Basazin Belhu2 and Jennifer Hadlock2, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Institute for Systems Biology, Seattle, WA

    Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
  • Abstract Number: 2191 • ACR Convergence 2022

    Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea

    In Ah Choi1, Ji Hyoun Kim2, Sung Hae Chang3, Hyun Jung Kim4 and Hyeong Sik Ahn4, 1Chungbuk National University, Cheongju, Republic of Korea, 2Chungbuk National University Hospital, Cheongju, Republic of Korea, 3Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, 4Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
  • Abstract Number: 2179 • ACR Convergence 2022

    Spatial and Single-Cell Transcriptomics Identify Alcam+ Macrophage / CD6+ T-Cell Interactions and Accumulation of IgG2b+ Class-Switched Plasma Cells in Marco+ Medullary Sinuses of Joint-Draining Popliteal Lymph Nodes in TNF-Tg Mice with Advanced Arthritis

    H. Mark Kenney1, Yue Peng2, Kiana Chen2, Javier Rangel-Moreno2, Elizabeth Pritchett2, Jeffrey Fox2, Benjamin Korman3, Jennifer Anolik2, Lianping Xing4, Christopher Ritchlin5, Edward Schwarz2 and Chia-Lung Wu2, 1University of Rochester Medical Center, Henrietta, NY, 2University of Rochester Medical Center, Rochester, NY, 3University of Rochester, Rochester, NY, 4University of Rochester Medical Center, Webster, NY, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

    Background/Purpose: Severe inflammatory-erosive arthritis in tumor necrosis factor transgenic (TNF-Tg) mice is associated with B-cell translocation into sinuses of joint-draining popliteal lymph nodes (PLNs) via…
  • Abstract Number: 2136 • ACR Convergence 2022

    Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components

    Arthur Kavanaugh1, Laura Coates2, Joseph Merola3, Philip J Mease4, Miroslawa Nowak5, Subhashis Banerjee5, Lauren Hippeli5 and Tom Lehman5, 1University of California San Diego, La Jolla, CA, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 5Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
  • Abstract Number: 2201 • ACR Convergence 2022

    Increased Economic Burden of Uveitis Among Patients with Psoriasis and Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2022

    M. Elaine Husni1, Jennifer Thorne2, Steve Peterson3, Natalie Shiff4, Shanti Neff-Baro5, Iris Lin5, Rachel Teneralli5, Oluwakayode Adejoro5 and Joseph Merola6, 1Cleveland Clinic, Cleveland, OH, 2Johns Hopkins Medicine, Baltimore, MD, 3Department of Immunology, Janssen Global Services, LLC, Horsham, PA, 4Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 5Janssen, Horsham, PA, 6Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Uveitis occurs more frequently in patients (pts) with psoriatic disease than in the general population,1-2 yet little is known about the increased burden associated…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 2200 • ACR Convergence 2022

    Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare

    Rahaf Baker1, Jing Li2, Rachael Stovall3, Jeffrey Curtis4, Fenglong Xie5, Jinoos Yazdany6 and Gabriela Schmajuk7, 1Alameda Highland Internal Medicine Residency, Oakland, CA, 2University of California, San Francisco, San Francisco, CA, 3University of California San Francisco, San Francisco, CA, 4University of Alabama at Birmingham, Hoover, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6UCSF, San Francisco, CA, 7UCSF / SFVA, San Francisco, CA

    Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
  • Abstract Number: 2190 • ACR Convergence 2022

    Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

    Yen Chen1, Alain Lescoat2, Dinesh Khanna3 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 4University of Michigan, Grosse Ile, MI

    Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
  • Abstract Number: 2147 • ACR Convergence 2022

    Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

    Filipe Pinheiro1, Rui Gaspar2, Bruno Fernandes3, Armando Peixoto2, Guilherme Macedo2 and Iva Brito4, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

    Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…
  • Abstract Number: 2207 • ACR Convergence 2022

    Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data

    Ruth Wittoek1, Céline Decock2, Nele Dewaele2, Lara Arnold3, Pieter baeyens4, Ignace Deschrijver4, Lisa Pardaens5, Ioannis Raftakis6, Thomas Renson7, Alexander D.J. Thooft8, Charline Rinkin9, Tine Vanhaverbeke5 and Caroline Verbist10, 1Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium, 2Ghent University, Faculty of Medicine, Ghent, Belgium, 3Dept. Of Rheumatology, Maastricht UMC+, Maastricht, Netherlands, 4Dept. of Radiology, Clinique de Flandre, Coudekerque-Branche, France, 5Ghent University, Faculty of Internal Medicine and Pediatrics, Gent, Belgium, 6Dept. of Rheumatology, CHU-Brugmann Hospital Brussels, Brussels, Belgium, 7Ghent University Hospital, Ghent, Belgium, 8Ghent University, Faculty of Internal Medicine and Pediatrics, Ghent, Belgium, 9Dept. of Rheumatology, CHU Liège, Liège, Belgium, 10Dept. of Rheumatology, AZ Delta, Roeselare, Belgium, Roeselare, Belgium

    Background/Purpose: Ultrasound is a highly valuable imaging modality to study joints in patients with rheumatic diseases. In children, the applicability is hampered because of lack…
  • Abstract Number: 2143 • ACR Convergence 2022

    Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

    Louis Bessette1, Georg Pongratz2, Luca Navarini3, Rodrigo Garcia Salinas4, Tianming Gao5, Marie-Claude Laliberté6, Ralph Lippe7 and Philip J Mease8, 1Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 2Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, 3Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, 4Hospital Italiano de La Plata, La Plata, Argentina, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Québec, QC, Canada, 7AbbVie, Inc, Wiesbaden, Germany, 8Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
  • Abstract Number: 2199 • ACR Convergence 2022

    Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

    Jeffrey Curtis1, Yujie Su2, Cassie Clinton2, Patrick Stewart3, Bryant England4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Bendcare, Boca Raton, FL, 4University of Nebraska Medical Center, Omaha, NE, 5FASTER, Hoover, AL

    Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
  • Abstract Number: 2206 • ACR Convergence 2022

    Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

    Lihi Eder1, Fangya Ma2, Josefina Marin3, Minna Kohler4, Janeth Yinh5, Ari Polachek6, Marcos Rosemffet7, Ernesto Rodriguez8, Ilaria Tinnazzi9, Amir Haddad10, Philippe Carron11, Mariana Alves Ferreira Martins12, Catherine Bakewell13, Fahmeen J. Afgani14, Richard Cook2, Sibel Aydin15 and Gurjit S. Kaeley16, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Tel Aviv Medical Center, Tel Aviv, Israel, 7Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 8Florida Medical Clinic, Tampa, FL, 9Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, 10Carmel Medical Centre, Haifa, Israel, 11Ghent University Hospital, Ghent, Belgium, 12São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, 13Intermountain Healthcare, Salt Lake City, UT, 14Women's College Hospital, Toronto, ON, Canada, 15University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, 16UF COM-J, Ponte Vedra Beach, FL

    Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…
  • Abstract Number: 2146 • ACR Convergence 2022

    Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

    Philip J Mease1, Rodrigo Luppino Assad2, Shigeyoshi Tsuji3, Pascal Richette4, Arathi Setty5, Erin McDearmon-Blondell6, Tianming Gao5, Sandra Ciecinski6 and Filip Van den bosch7, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, 3Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 4Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

    Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
  • Abstract Number: 2030 • ACR Convergence 2022

    Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome

    Jonathan Hubbard1, Kim Campbell1, Kathy Sivils1, Robert Hoffman1, Kim Hung Lo1, Jocelyn Leu1, Sophia Liva1, Qing Zuraw1, Anne Stevens1, Leona Ling2, Keith Karcher3, Sindhu Ramchandren3, Hong Sun3, Hal Scofield4, Daniel Wallace5 and Raphaèle Seror6, 1Janssen Research and Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Cambridge, MA, 3Janssen Research & Development, LLC, Titusville, NJ, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
  • « Previous Page
  • 1
  • …
  • 415
  • 416
  • 417
  • 418
  • 419
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology